Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25004
Abstract: Patients with acute myeloid leukemia (AML) in relapse or refractory to induction therapy have a dismal prognosis. Allogeneic hematopoietic stem cell transplantation is the only curative option. In these patients, we aimed to compare the… read more here.
Keywords: refractory relapsed; myeloid leukemia; stem cell; conditioning regimen ... See more keywords
Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.2865
Abstract: Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18‐ to 65‐year‐old AML patients refractory to first‐line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7… read more here.
Keywords: allo hsct; relapsed acute; clofarabine; refractory relapsed ... See more keywords
Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5765
Abstract: Autologous stem cell transplantation (ASCT) is the standard treatment strategy for refractory or relapsed classical Hodgkin lymphoma (R/R cHL). However, a single transplantation is insufficient to cure the disease because of unfavorable risk factors. Herein,… read more here.
Keywords: refractory relapsed; relapsed classical; stem cell; cell transplantation ... See more keywords
Anti‐CLL1‐based CAR T‐cells with 4‐1‐BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5916
Abstract: Though the efficacy of anti C‐type lectin‐like molecule‐1 (CLL1) CAR T‐cells in refractory/relapsed acute myeloid leukemia (R/R‐AML) have been occasionally reported, the influence of co‐stimulatory domain CAR T‐cells is not investigated so far. read more here.
Keywords: refractory relapsed; myeloid leukemia; car; acute myeloid ... See more keywords
Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06310-4
Abstract: There has been a growing concern regarding the adverse events including hematological malignancies which occurring in the later stages following CAR-T immunotherapy. Here, we presented a case of secondary MDS/AML following CAR-T immunotherapy in our… read more here.
Keywords: poor prognosis; therapy; car immunotherapy; refractory relapsed ... See more keywords
Salvage therapy with 2-chlorodeoxyadenosine for refractory and relapsed pediatric Langerhans cell histiocytosis: an updated nationwide survey in Japan
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-03073-8
Abstract: The prospective clinical trials conducted by the Histiocyte Society and the Japan LCH Study Group have markedly improved overall survival rates of pediatric patients with Langerhans cell histiocytosis (LCH). However, some patients were refractory to… read more here.
Keywords: refractory relapsed; group; study; disease ... See more keywords
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2017.07.008
Abstract: BACKGROUND AIMS Activated NK cells (aNK) generated by expansion of a human interleukin-2-dependent NK cell line (NK-92) were shown to mediate strong anti-leukemia activity. This phase 1 study evaluated feasibility, safety, and activity of aNK… read more here.
Keywords: ank cells; cell; refractory relapsed; patients refractory ... See more keywords
Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-019-0690-2
Abstract: Optimization of the salvage regimen is required to improve prognosis in primary refractory or relapsed acute myeloid leukemia (AML). In fit patients, a bridge to allogeneic transplant is the primary purpose of salvage. We tested… read more here.
Keywords: relapsed acute; bridge allogeneic; refractory relapsed; salvage ... See more keywords
Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients.
Sign Up to like & getrecommendations! Published in 2025 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaf140
Abstract: BACKGROUND Amrubicin monotherapy has been used in Japan for patients with refractory, relapsed, small cell lung cancer (SCLC). However, the clinical guidelines do not specify a recommended initial dose for elderly patients. This retrospective study… read more here.
Keywords: dose; amrubicin monotherapy; elderly patients; refractory relapsed ... See more keywords
Naxitamab-combination Therapy for the Treatment of Patients With Refractory and/or Relapsed High-risk Neuroblastoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of pediatric hematology/oncology"
DOI: 10.1097/mph.0000000000003096
Abstract: Approved treatments for patients with refractory and/or relapsed (R/R) high-risk (HR) neuroblastoma are limited, and there is a need for new treatment combinations. In this case series, 4 patients were treated with the anti-GD2 monoclonal… read more here.
Keywords: treatment; risk neuroblastoma; patients refractory; high risk ... See more keywords
Less nephrotoxicity of paclitaxel and ifosfamide plus nedaplatin for refractory or relapsed germ cell tumors in patients with impaired renal function
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Urology"
DOI: 10.1111/iju.14147
Abstract: To determine the safety and efficacy of the combined regimen of paclitaxel and ifosfamide plus nedaplatin for patients with refractory or relapsed germ cell tumors and impaired renal function. read more here.
Keywords: plus nedaplatin; refractory relapsed; paclitaxel ifosfamide; germ cell ... See more keywords